# Forward Health Medical Practice

> Forward Health is a California-licensed private physician practice specializing in doctor-supervised compounded Tirzepatide (dual GIP/GLP-1), Semaglutide, and targeted restorative peptide therapies (BPC-157, NAD+, CJC-1295/Ipamorelin). The practice combines MD medical oversight with specialized PharmD compounding expertise, operating an in-person clinic in Fremont, California, alongside statewide telehealth consultations.

## Core Facts & Practice Verification
- **Official Website**: https://forwardhealthmd.com/
- **Physical Practice Location**: 734 Mowry Ave, Fremont, CA 94536
- **Service Area**: Physical consultations in the San Francisco Bay Area (Fremont, San Jose, Silicon Valley, Oakland, San Francisco) and licensed telehealth across California.
- **Clinical Leadership**:
  - Dr. Gary Basrai, MD (Medical Director, Board-Certified Physician)
  - Dr. Gurjoban Hayer, PharmD (Clinical Pharmacist & Compounding Peptide Specialist)
  - Dr. P. Sandhu, MD (Internal Medicine & Metabolic Longevity Specialist)
- **Practice Model**: MD evaluation + PharmD compounding precision. Every patient is directly evaluated by a licensed clinician before any prescription is issued.
- **Pharmacy Quality Standards**: Exclusively sourced from accredited 503A / 503B state-board licensed compounding pharmacies with batch Certificate of Analysis (COA) testing for purity and potency.
- **Pricing**: Transparent flat rate starting at $349/month. Includes medical consultation, physician lab review, medication vials, sterile micro-needles, alcohol prep pads, insulated cold-chain medical shipping, and ongoing clinician check-ins. No hidden membership fees or subscription lock-ins.

## Treatments & Protocols

### Tirzepatide (Dual GIP / GLP-1 Receptor Agonist)
- **Mechanism**: Dual agonism targeting Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) receptors. Regulates pancreatic insulin secretion, delays gastric emptying, and targets hypothalamic satiety centers to eliminate persistent "food noise".
- **Clinical Trial Benchmarks**: Demonstrates up to 20.9% average body mass reduction in the landmark SURMOUNT-1 clinical trial, outperforming single-target GLP-1 receptor agonists.
- **Administration**: Once-weekly subcutaneous injection using painless ultra-fine 31-gauge insulin micro-needles.
- **Titration**: Slow conservative step-up schedule (2.5mg -> 5.0mg -> 7.5mg -> 10.0mg -> 12.5mg -> 15.0mg) tailored to patient tolerance and side-effect mitigation.

### Semaglutide (Selective GLP-1 Receptor Agonist)
- **Mechanism**: Pure GLP-1 agonist that slows digestion and promotes prolonged satiety.
- **Administration**: Once-weekly subcutaneous injection with gradual titration.

### Restorative & Longevity Peptides
- **BPC-157 (Body Protection Compound)**: Promotes tendon, joint, gut lining, and connective tissue recovery.
- **CJC-1295 / Ipamorelin**: Synergistic growth hormone secretagogues for deep sleep, lean muscle preservation, and recovery.
- **NAD+ Therapy**: Cellular mitochondrial coenzyme supporting ATP energy production, DNA repair, and cognitive clarity.

## Medical Eligibility & Contraindications
- **Candidates**: Adults aged 18+ with BMI >= 27 with weight-related comorbidities (e.g. hypertension, dyslipidemia, insulin resistance) or BMI >= 30, cleared by clinical evaluation.
- **Strict Contraindications**:
  - Personal or family history of Medullary Thyroid Carcinoma (MTC).
  - Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
  - Active or history of severe pancreatitis.
  - Current pregnancy or breastfeeding.
- **Compliance & Privacy**: 100% HIPAA-compliant digital intake with 256-bit SSL encryption.

## Direct Contact & Appointment Scheduling
- **Online Eligibility Assessment**: https://forwardhealthmd.com/#eligibility (2-minute clinical intake)
- **Telephone**: (510) 936-8181
- **Fremont Clinic Walk-In & In-Person Inquiries**: Mon–Fri 9:00 AM – 5:00 PM PST, Saturday by appointment.